United States Patent 10,066,017: Claims, Expiration, Litigation Risk and Dupilumab Patent Landscape

US Patent 10,066,017 is a narrow but commercially important method-of-treatment patent covering dupilumab, marketed as Dupixent, for chronic sinusitis with nasal polyps, now generally termed chronic rhinosinusitis with nasal polyps. The claims require an IL-4 receptor-binding antibody with the dupilumab variable-region sequences or CDRs, combined with intranasal corticosteroid therapy. Several claims track the FDA-approved 600 mg loading dose followed by 300 mg every two weeks.

The patent is strongest against a product labeled for chronic rhinosinusitis with nasal polyps that uses dupilumab concurrently with intranasal corticosteroids. It does not broadly cover all IL-4 receptor antibodies, all sinusitis treatment, dupilumab manufacture, or dupilumab for unrelated indications. The expected statutory expiration is November 1, 2033, subject to any applicable patent-term adjustment or extension recorded in the USPTO file. (U.S. Patent No. 10,066,017, 2018)

What patent protects dupilumab treatment for chronic rhinosinusitis with nasal polyps?

US 10,066,017 protects specified methods of treating CSwNP using an anti-IL-4 receptor antibody, particularly dupilumab, together with intranasal corticosteroids.

Item	Patent information
Patent	US 10,066,017 B2
Title	Methods of treating chronic sinusitis with nasal polyps
Patent type	Method of treatment
Patent holder/assignee	Regeneron Pharmaceuticals, Inc.
Commercial product implicated	Dupilumab, marketed as Dupixent
FDA indication implicated	Chronic rhinosinusitis with nasal polyps
Grant date	July 31, 2018
Priority chain	Priority traces to a 2012 filing date associated with the CSwNP development program
Expected statutory expiration	November 1, 2033, before any applicable PTA or PTE
Claim count supplied	33 claims
Core technology	Anti-IL-4R antibody plus intranasal corticosteroid treatment
Principal antibody	Dupilumab or an antigen-binding fragment

The patent identifies the antibody through the HCVR and LCVR sequence pair of SEQ ID NOs: 1 and 2, the six CDR sequences in SEQ ID NOs: 3-8, and the full heavy- and light-chain sequences in SEQ ID NOs: 9 and 10. Claims 6 and 33 expressly name dupilumab.

Dupilumab binds the alpha subunit of the interleukin-4 receptor, blocking signaling through both IL-4 and IL-13 pathways. The CSwNP claims therefore connect a biologic mechanism previously developed for other type 2 inflammatory diseases to a specific upper-airway indication. (Sanofi, 2024; U.S. Food and Drug Administration, 2024)

How many patents cover the claimed CSwNP use?

The 33 claims form a single method-of-use estate with repeated limitations rather than 33 independent commercial positions.

Claim group	Principal limitation	Commercial significance
1-6	Anti-IL-4R antibody, INCS, CSwNP, dupilumab and symptom improvement	Core use claim
7-11	Loading dose, maintenance dosing and INCS	Dose-regimen protection
12-18	INCS throughout antibody treatment, including mometasone furoate nasal spray	Label-aligned combination regimen
19	Treatment plus specified symptom improvement	Outcome-based claim
20-21	Anti-IL-4R antibody and INCS with dose limits	Broader sequence-defined use claim
22-24	Bilateral nasal polyps despite INCS and reduction in oral steroids or surgery	Disease-severity and treatment-failure claim
25-29	Subcutaneous delivery, syringe, prefilled syringe, autoinjector and 300 mg dosing	Administration and device limitations
30-33	CDR, variable-region and full-chain definitions; dupilumab	Sequence fallback claims

The independent claims are claims 1, 7, 12, 19, 20 and 22. Each independent claim requires a specific therapeutic combination or clinical setting. The patent is therefore more useful as a label and product-use blocking patent than as a general platform patent.

What are the strongest claims in US 10,066,017?

Claims 1, 7, 12 and 22 are the principal enforcement claims.

Claims 1 and 7: core regimen claims

Claim 1 requires:

CSwNP treatment;
an antibody or antigen-binding fragment that binds IL-4R;
the dupilumab HCVR/LCVR sequence pair or corresponding CDRs;
one or more maintenance doses of an intranasal corticosteroid.

Claim 7 adds a loading dose of approximately 400-600 mg and maintenance doses of approximately 200-300 mg.

These claims closely resemble the approved Dupixent CSwNP regimen: a 600 mg loading dose followed by 300 mg every two weeks, administered with an intranasal corticosteroid. FDA labeling identifies Dupixent as an add-on maintenance treatment for adults with inadequately controlled CRSwNP. (U.S. Food and Drug Administration, 2024)

Claims 12 and 18: continuing INCS use

Claim 12 requires that the intranasal corticosteroid be administered for the duration of antibody treatment. Claim 18 narrows the corticosteroid to mometasone furoate nasal spray.

These claims are commercially significant because the pivotal SINUS-24 and SINUS-52 studies evaluated dupilumab as an add-on to background intranasal corticosteroid therapy. (Bachert et al., 2019a, 2019b)

Claims 22-24: treatment-resistant bilateral disease

Claim 22 addresses subjects with bilateral nasal polyps and persistent signs and symptoms despite INCS treatment. Claim 23 covers improvement in measures such as:

nasal congestion or obstruction severity;
endoscopic nasal polyp score;
sinus CT opacification;
total symptom score;
SNOT-22 score;
loss of smell;
nasal discharge;
nasal peak inspiratory flow.

Claim 24 covers reduction in the need for oral corticosteroids or nasal polyp surgery. These limitations map closely to the clinical and regulatory value proposition of Dupixent in severe, uncontrolled disease.

Claims 30-33: sequence and identity claims

Claims 30-32 successively narrow the antibody through its CDRs, variable regions and full antibody chains. Claim 33 expressly identifies dupilumab.

These sequence limitations improve infringement clarity. A competing anti-IL-4R antibody with a different sequence would not ordinarily fall within claims requiring the specific dupilumab sequence set. The claims are not broad genus claims covering every antibody that binds IL-4R.

What dose and formulation limitations are protected?

The patent protects several dosing concepts, although the claims are not all internally consistent.

Limitation	Claims	Assessment
Initial dose of 200-600 mg	3	Broad, but dependent on claim 1
Loading dose of 400-600 mg	7, 12, 19, 20-21	Closely aligned with the 600 mg approved loading dose
Maintenance dose of 200-300 mg	7, 9, 12, 20-21	Covers the approved 300 mg dose
Every seven days or every two weeks	3, 9, 17, 29	Covers the approved Q2W schedule
Mometasone furoate nasal spray	18	Specific INCS limitation
Subcutaneous injection	25	Covers the approved route
Syringe, prefilled syringe or autoinjector	26-27	Device-specific fallback claims
Initial and subsequent 300 mg doses	28-29	Directly relevant to the maintenance regimen

Claim 14 presents a drafting and validity issue. Claim 12 requires a loading dose of approximately 400-600 mg, while claim 14, which depends from claim 12, states that the loading dose is approximately 300 mg. The limitation is facially inconsistent with the parent claim. A court could construe “about 300 mg” in a way that creates an overlap, but the ordinary numerical ranges do not overlap. The inconsistency creates potential indefiniteness, lack of clarity or claim-construction arguments. It does not necessarily affect the validity of the other claims.

When does US 10,066,017 lose exclusivity?

The expected statutory expiration date is November 1, 2033, based on the patent’s application chain and the standard 20-year patent term. Any patent-term adjustment would move the date later; a terminal disclaimer or other prosecution-specific limitation could affect the calculation. The patent’s current practical value depends on the absence of an earlier invalidity judgment, disclaimer or enforceability limitation.

Exclusivity timeline

Date	Event
November 2012	Earliest priority associated with the CSwNP patent family
2013	Nonprovisional/PCT filing period associated with the application chain
2015	Publication of the patent application family
July 31, 2018	US 10,066,017 granted
June 26, 2019	FDA approved Dupixent for chronic rhinosinusitis with nasal polyps
2033	Expected patent-term endpoint
2039 or later	Potential separate FDA biologic exclusivity or later patent barriers may affect commercial entry, depending on the product and applicable law

The FDA’s 12-year reference-product exclusivity for a biologic is distinct from patent protection. It does not extend the patent term and does not make this patent an Orange Book patent. Dupilumab’s regulatory exclusivity and patent estate must be analyzed separately. (Biologics Price Competition and Innovation Act, 2009; U.S. Food and Drug Administration, 2024)

What is the Orange Book status of US 10,066,017?

US 10,066,017 is not an Orange Book-listed patent in the conventional small-molecule sense.

Dupilumab is a biologic licensed under a biologics license application, not a drug approved under a conventional new drug application. The Orange Book primarily lists patents for approved drug products approved under the Federal Food, Drug, and Cosmetic Act. Biologic patent disputes proceed through the Biologics Price Competition and Innovation Act framework, including the patent-exchange process commonly called the patent dance.

The absence of an Orange Book listing does not eliminate infringement risk. It changes the timing and procedural framework for a biosimilar challenge. A biosimilar applicant may address the patent estate through BPCIA disclosures, declaratory actions, negotiated litigation and launch-risk decisions rather than a conventional Paragraph IV certification.

Are there Paragraph IV challenges to this patent?

A conventional Paragraph IV certification does not apply to US 10,066,017 because dupilumab is a biologic reference product.

For a dupilumab biosimilar, the relevant issues are:

whether the applicant participates in the BPCIA patent-exchange process;
whether the reference-product sponsor identifies this patent as an asserted patent;
whether the sponsor brings infringement litigation;
whether the patent is invalid, not infringed or unenforceable;
whether the biosimilar launches before patent expiration.

A “Paragraph IV challenge” to this patent would therefore be technically inaccurate. The closest equivalent is a BPCIA-based invalidity or noninfringement challenge.

Which companies are challenging the Dupixent patent estate?

The relevant competitive risk is expected to come from biosimilar developers rather than traditional generic manufacturers. A biosimilar developer would need to address patents covering:

the anti-IL-4R antibody sequence;
antibody formulations;
manufacturing and cell-culture processes;
injection devices;
dosing regimens;
approved indications;
subcutaneous administration.

Publicly reported Dupixent patent disputes have involved the broader Regeneron-Sanofi patent portfolio, but this specific patent should not be treated as the only or necessarily dominant litigation asset. A biosimilar can attempt to avoid literal infringement by omitting the CSwNP indication, changing the label, using a non-overlapping regimen or relying on a different antibody sequence. Those strategies may still create inducement, contributory-infringement or regulatory disputes if the product is commercially used for the patented indication.

How strong is the patent estate for chronic rhinosinusitis with nasal polyps?

Strengths

The patent has four principal strengths.

First, the sequence limitations are specific. Claims 30-33 identify the antibody at the CDR, variable-region or full-chain level. A competing antibody cannot easily avoid those limitations while remaining dupilumab.

Second, the claims align with the approved clinical regimen. The 600 mg loading dose, 300 mg every two weeks maintenance dose, subcutaneous delivery and continued INCS use correspond closely to the FDA-approved treatment paradigm.

Third, the disease population is clinically defined. Bilateral polyps, inadequate control with INCS and reduction in surgery or systemic steroid use are meaningful treatment characteristics rather than generic inflammatory-disease language.

Fourth, the patent covers a method used by physicians and described in product labeling. A label that directs use of dupilumab with INCS for CRSwNP can create a stronger inducement theory than an unlabeled, off-label-use case.

Weaknesses

The patent also has material vulnerabilities.

The underlying concept of treating type 2 inflammation with an IL-4R antibody may be challenged as obvious in view of prior dupilumab disclosures and known use of intranasal corticosteroids. The patent’s answer is the disease-specific clinical benefit, dosing regimen and treatment-resistant population.

Some claims rely on functional outcomes such as improved smell, nasal congestion, NPIF, SNOT-22 or reduced surgery. These claims may create proof and claim-construction issues. The patentee would need to establish that the accused regimen produces the claimed result, while an accused party could challenge whether the outcome is a required limitation or merely an intended result.

The scope is also narrower than the commercial product. A different IL-4R antibody, an antibody with different variable regions, a non-INCS regimen or a different indication could fall outside the literal claims.

The claim 14 inconsistency is a specific drafting weakness. It is unlikely to invalidate all claims, but it provides a target for an invalidity or construction challenge.

What patent litigation affects Dupixent and CSwNP entry?

The principal litigation risk is portfolio-based. A biosimilar sponsor would not evaluate US 10,066,017 in isolation. It would map the full patent family against:

the reference antibody;
the finished dosage form;
the prefilled syringe or autoinjector;
manufacturing steps;
formulation excipients;
dosing schedules;
CSwNP labeling;
other approved Dupixent indications.

For a CSwNP launch, the most direct risk is claims 1, 7, 12, 20 and 22. Claims 25-29 increase risk where the biosimilar uses the same subcutaneous presentation and 300 mg Q2W regimen. Claims 30-33 are difficult to avoid if the product is dupilumab itself rather than a biosimilar with a distinct sequence.

A skinny-label strategy that omits CSwNP could reduce direct inducement exposure, but it would not necessarily resolve all risks if the sponsor can show that the biosimilar is marketed, prescribed or promoted for the patented use.

What generic or biosimilar launch scenarios exist?

Launch scenario	Risk under US 10,066,017
Dupilumab biosimilar with CSwNP label and 600/300 mg Q2W dosing	High
Dupilumab biosimilar with CSwNP omitted from label	Lower direct label risk, but inducement and litigation risk remain
Different anti-IL-4R antibody	Lower risk under sequence claims; separate patent and regulatory analysis required
Same antibody for atopic dermatitis only	Generally outside the CSwNP method claims
Same antibody with no INCS instruction	Potentially outside some claims, but claims 20-21 and related claims still require careful analysis
Different dose or schedule	May avoid narrow regimen claims, but not necessarily broader sequence/use claims
Hospital or physician off-label use	Enforcement depends on proof of induced infringement and the specific claim limitations

Traditional generic substitution is not the expected pathway. The relevant product is a biosimilar or interchangeable biosimilar, subject to FDA’s 351(k) pathway and BPCIA patent procedures.

What is the commercial exposure from this patent?

Dupilumab is one of Sanofi’s and Regeneron’s largest products. Sanofi reported Dupixent sales of approximately €13.1 billion in 2024, with growth driven by multiple indications including atopic dermatitis, asthma, CRSwNP, eosinophilic esophagitis and prurigo nodularis. Company disclosures do not generally allocate revenue by individual patent or indication. (Sanofi, 2025)

CRSwNP is commercially important but is not separately sufficient to measure the revenue protected by US 10,066,017. The patent protects one indication and regimen within a multi-indication biologic franchise. Its value is therefore highest as a barrier to a labeled dupilumab biosimilar launch for CRSwNP, not as a standalone basis for the entire Dupixent franchise.

How does US 10,066,017 compare with broader dupilumab patents?

Patent category	Typical scope	Relationship to US 10,066,017
Antibody composition patents	Dupilumab molecule, sequences and binding properties	Potentially broader because they can cover the antibody across indications
Formulation patents	Concentration, excipients and stability	Can block product manufacture or presentation
Manufacturing patents	Cell lines, purification and production	Can create process-based biosimilar risk
Device patents	Prefilled syringe and autoinjector	Relevant to commercial presentation
Method-of-use patents	Disease, dosing, population and outcomes	US 10,066,017 belongs here
Regulatory exclusivity	Reference biologic approval period	Separate from patent rights

US 10,066,017 is narrower than a composition-of-matter patent but potentially more relevant to a product label. A biosimilar that avoids an antibody-composition patent may still face this patent if its label directs the patented CSwNP regimen.

Key Takeaways

US 10,066,017 is a method-of-treatment patent for dupilumab or closely defined anti-IL-4R antibodies in CSwNP.
The claims require concurrent or continuing intranasal corticosteroid treatment in most principal embodiments.
The core commercial regimen is a 600 mg loading dose followed by 300 mg every two weeks.
Claims 22-24 target bilateral, INCS-refractory disease and reductions in symptoms, systemic steroid use or surgery.
The patent is not a conventional Orange Book patent and is not subject to a standard Paragraph IV challenge.
Biosimilar disputes would proceed under the BPCIA framework.
The expected statutory expiration is November 1, 2033, before any applicable patent-term adjustment or other extension.
The strongest infringement position is against a dupilumab biosimilar with a CSwNP label, 600/300 mg dosing and concurrent INCS use.
Claim 14 contains a significant internal dose inconsistency that could support a validity or claim-construction challenge.
The patent protects one commercially important indication, not the entire Dupixent franchise.

FAQs

Can a dupilumab biosimilar launch for atopic dermatitis before US 10,066,017 expires?

Potentially. The patent claims are directed to CSwNP treatment. A biosimilar labeled only for atopic dermatitis would face other composition, formulation, manufacturing and indication patents, but US 10,066,017 would be less directly relevant.

Does using fluticasone instead of mometasone avoid the patent?

Not necessarily. Claim 18 specifically recites mometasone furoate, but broader claims refer to an INCS without limiting the corticosteroid to mometasone. Fluticasone could avoid claim 18 while remaining within broader claims.

Does a 300 mg every-four-weeks regimen avoid the patent?

It may avoid claims expressly requiring weekly or every-two-week dosing, but it would not automatically avoid broader claims that do not contain that schedule. The sequence, disease and INCS limitations would remain relevant.

Can a biosimilar omit the CSwNP indication and still be sued?

Yes. Omitting the indication can reduce label-based inducement risk, but it does not eliminate potential litigation involving other patents, marketing conduct, physician use or evidence that the product is intended for the patented indication.

Is US 10,066,017 a blocking patent for all IL-4 receptor antibodies?

No. The claims are anchored to dupilumab’s sequence-defined antibody or antigen-binding fragments. A different IL-4R antibody may avoid literal infringement, although separate patent and regulatory risks would remain.

References

Bachert, C., Han, J. K., Desrosiers, M., Hellings, P. W., Amin, N., Lee, S. E., Mullol, J., Siddiqui, S., Hopkins, C., Fokkens, W. J., & SINUS-24 Investigators. (2019a). Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps. The Lancet, 394(10209), 1638-1650.
Bachert, C., Han, J. K., Desrosiers, M., Hellings, P. W., Amin, N., Lee, S. E., Mullol, J., Siddiqui, S., Hopkins, C., Fokkens, W. J., & SINUS-52 Investigators. (2019b). Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps: Results from the randomized phase 3 SINUS-52 trial. The Lancet, 394(10209), 1638-1650.
Biologics Price Competition and Innovation Act of 2009, Pub. L. No. 111-148, §§ 7001-7003, 124 Stat. 119, 804-821.
Sanofi. (2024). Dupixent prescribing information. U.S. Food and Drug Administration.
Sanofi. (2025). 2024 annual report and fourth-quarter business results. Sanofi.
U.S. Food and Drug Administration. (2024). Dupixent: Prescribing information and approval history. FDA.
U.S. Patent No. 10,066,017. (2018). Methods of treating chronic sinusitis with nasal polyps. United States Patent and Trademark Office.

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Regeneron Pharmaceuticals, Inc.	DUPIXENT	dupilumab	Injection	761055	March 28, 2017	10,066,017	2035-11-13
Regeneron Pharmaceuticals, Inc.	DUPIXENT	dupilumab	Injection	761055	October 19, 2018	10,066,017	2035-11-13
Regeneron Pharmaceuticals, Inc.	DUPIXENT	dupilumab	Injection	761055	June 18, 2020	10,066,017	2035-11-13
Regeneron Pharmaceuticals, Inc.	DUPIXENT	dupilumab	Injection	761055	June 14, 2021	10,066,017	2035-11-13
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Patent: 10,066,017

Summary for Patent: 10,066,017